cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Mersana Therapeutics Inc
8 own
8 watching
Current Price
$0
$0.03
(0.37%)
logo-mrsn
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
662.47M
52-Week High
52-Week High
8.3379
52-Week Low
52-Week Low
2.68
Average Volume
Average Volume
0.79M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization662.47M
icon52-Week High8.3379
icon52-Week Low2.68
iconAverage Volume0.79M
iconDividend Yield--
iconP/E Ratio--
What does the Mersana Therapeutics Inc do?
N/A
Read More
How much money does Mersana Therapeutics Inc make?
News & Events about Mersana Therapeutics Inc.
Globe Newswire
7hours ago
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
Globe Newswire
1day ago
Company plans to report interim data for the combination of UpRi with carboplatin inthe second half of 2023CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
Globe Newswire
8days ago
First Immunosynthen ADC product candidate enters the clinicCAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers ...
Globe Newswire
27days ago
Report top-line data from UPLIFT registrational trial in mid-2023, submit potential BLA around year end 2023, and prepare for potential U.S. commercial launch in 2024Advance Phase 3 UP-NEXT and Phase 1 UPGRADE-A trials in platinum-sensitive ovarian cancerAdvance XMT-1660 and XMT-2056 Phase 1 trials ...
Globe Newswire
1month ago
CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
Frequently Asked Questions
Frequently Asked Questions
What is Mersana Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Mersana Therapeutics Inc shares?
plus_minus_icon
How can I buy Mersana Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Mersana Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Mersana Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Mersana Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Mersana Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Mersana Therapeutics Inc?
plus_minus_icon
What percentage is Mersana Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Mersana Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.03
(0.37%)
logo-mrsn
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00